<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Evaluation and management of treatment-resistant schizophrenia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Evaluation and management of treatment-resistant schizophrenia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Evaluation and management of treatment-resistant schizophrenia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Kane, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jose M Rubio, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Taishiro Kishimoto, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christoph U Correll, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen Marder, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Friedman, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 09, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H262343245">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antipsychotic medication is first-line treatment for schizophrenia. Most patients show substantial improvement in psychotic symptoms in response to antipsychotics; however, for many, improvement is insufficient to meet stringent criteria for remission, and a substantial proportion experience residual treatment-resistant symptoms.
        </p>
        <p>
         Patients who do not respond adequately to antipsychotics should be reevaluated to rule out or address causes other than nonresponsiveness to medication (ie, pseudoresistance). Current medication and psychosocial interventions should be optimized. Treatment strategies for patients who remain incompletely responsive to antipsychotic medications include changes to antipsychotic doses and drugs, use of
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         (in eligible patients), and drug augmentation.
        </p>
        <p>
         This topic addresses the evaluation and management of treatment-resistant schizophrenia. The epidemiology, pathogenesis, clinical manifestations, course, assessment, diagnosis and treatment of schizophrenia are reviewed separately, as are the presentation and treatment of anxiety and depression co-occurring with schizophrenia and guidelines for prescribing
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/14804.html" rel="external">
          "Schizophrenia in adults: Epidemiology and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6962.html" rel="external">
          "Schizophrenia in adults: Clinical features, assessment, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">
          "Schizophrenia in adults: Maintenance therapy and side effect management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15250.html" rel="external">
          "Schizophrenia in adults: Pharmacotherapy with long-acting injectable antipsychotic medication"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7798.html" rel="external">
          "Co-occurring schizophrenia and substance use disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15259.html" rel="external">
          "Anxiety in schizophrenia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14791.html" rel="external">
          "Depression in schizophrenia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14772.html" rel="external">
          "Schizophrenia in adults: Guidelines for prescribing clozapine"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17442617">
         <span class="h1">
          DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epidemiologic studies of treatment-resistant schizophrenia and practice guidelines on its treatment are based on varying definitions of treatment-resistant schizophrenia, limiting the utility of the results [
         <a href="#rid1">
          1
         </a>
         ]. In response, in 2017 an international panel of experts, the Treatment Response and Resistance in Psychosis (TRRIP) Working Group, published consensus-based criteria (minimal and optimal) for the diagnosis of treatment-resistant schizophrenia. Their work included specifications for the collection of clinical data needed to establish the diagnosis [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Minimal TRRIP criteria for treatment-resistant schizophrenia
         </strong>
         – Based on cross-sectional clinical assessment supplemented by collateral sources of information (eg, medical record documentation, caregiver’s report).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diagnosis – DSM-5 diagnosis of schizophrenia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Symptom severity – At least moderate symptom severity (&gt;3 in psychotic symptom items) as rated using a standardized scale (eg, Positive and Negative Syndrome Scale [PANSS] or Brief Psychiatric Rating Scale [BPRS]).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Functional impairment
         <strong>
         </strong>
         – At least moderate impairment measured using a validated scale (eg, Social and Occupational Functioning Assessment Scale).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prior treatment – At least two trials of ≥6 weeks at a therapeutic dose (equivalent to ≥600 mg
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         ) with adherence ≥80 percent of prescribed doses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Optimal TRRIP criteria
         </strong>
         <strong>
          for treatment-resistant schizophrenia
         </strong>
         – The minimal criteria (above) with the addition of:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prospective evaluation of symptom severity using a standardized scale (eg, PANSS or BPRS) confirming &lt;20 percent symptom reduction over six weeks of treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         One of the two antipsychotic trials should be a long-acting injectable antipsychotic. (See
         <a class="medical medical_review" href="/z/d/html/15250.html" rel="external">
          "Schizophrenia in adults: Pharmacotherapy with long-acting injectable antipsychotic medication"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antipsychotic adherence should be confirmed by ≥2 antipsychotic plasma levels.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H412052632">
         <span class="h1">
          PREVALENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         A sizeable proportion of patients with schizophrenia do not respond sufficiently to antipsychotics [
         <a href="#rid3">
          3
         </a>
         ]; however, the absence of consensus criteria for defining treatment-resistant schizophrenia prior to 2017 limited efforts to determine the prevalence of the condition. Estimates based on varying definitions have ranged from 66.3 to 83.4 percent:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2017 meta-analysis of placebo-controlled studies in patients with acute exacerbation of schizophrenia, 49 percent of patients experienced little or no response (&gt;20 percent of symptom improvement) with one trial of antipsychotic medication [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a multiple-phase trial in individuals with a first psychotic episode, only 16.6 percent of individuals who had failed the first antipsychotic trial met response criteria (ie, Clinical Global Impressions Scale &gt;2 [much improved]) with a second antipsychotic trial [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a prospective, observational study of 341 patients with schizophrenia or schizoaffective disorder treated with an antipsychotic medication in Belgium, 71 percent did not achieve severity and duration criteria for remission [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A cohort study that followed individuals with a first episode of schizophrenia for the first 10 years after diagnosis found that 23 percent met treatment-resistance criteria, of whom 84 percent were so from treatment onset [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a cohort of first episode cohort of patients with schizophrenia followed for five years, 33.7 percent met treatment-resistance criteria, of whom 70 percent were treatment resistant from illness onset [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         “Ultra-resistance” (ie, schizophrenia patients resistant to both non-clozapine antipsychotics and
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         ) was estimated at 12 to 20 percent of treated patients in a systematic review and meta-analysis of 21 clinical trials with 25 treatment comparisons. A pooled response rate to clozapine of 40 percent was found among schizophrenia patients who had previously demonstrated resistance to non-clozapine antipsychotics [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17442624">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our clinical approach to diagnosing treatment-resistant schizophrenia is based on the Treatment Response and Resistance in Psychosis Working Group criteria. The sections that follow provide more detailed information and supporting evidence for each step.
        </p>
        <p class="headingAnchor" id="H1682469219">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epidemiologic data suggest that the diagnosis of treatment-resistant schizophrenia may often be overlooked [
         <a href="#rid9">
          9,10
         </a>
         ], and when made, it is often years after the criteria were met [
         <a href="#rid9">
          9
         </a>
         ]. For this reason, it is important that clinicians are proactive in the evaluation and management of residual symptoms despite ongoing treatment.
        </p>
        <p>
         The treatment of choice for treatment-resistant schizophrenia is
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         , which has superior efficacy in this population compared with other antipsychotics [
         <a href="#rid8">
          8,11-13
         </a>
         ]. However, because clozapine can cause significant adverse effects, there are a number of steps that should be taken prior to a clozapine trial:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assess for other causes of residual schizophrenia symptoms (ie, pseudoresistance) (see
         <a class="local">
          'Assess for pseudoresistance'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Optimizing nonpharmacologic treatment (see
         <a class="local">
          'Adequacy of nonpharmacologic treatment'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Optimizing current antipsychotic drug treatment (see
         <a class="local">
          'Adequacy of antipsychotic trials'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         If these steps do not lead to symptom remission, and the patient has had at least two antipsychotic trials of six weeks or more at maximally tolerated doses while monitoring for treatment adherence, we would then proceed to a
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         trial. (See
         <a class="local">
          'Clozapine'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H365611955">
         <span class="h2">
          Assess for pseudoresistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         When a patient with schizophrenia appears to be resistant to standard antipsychotic treatment, he or she should be evaluated for causes of pseudoresistance or treatment nonresponse due to reasons other than medication nonresponse. Findings of other factors causing or contributing to the persistence of symptoms can prompt changes to the patient’s clinical management other than antipsychotic drug treatment.
        </p>
        <p class="headingAnchor" id="H412052925">
         <span class="h3">
          Reevaluation of the primary diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reevaluation of the primary diagnosis is indicated in patients who are not responsive to antipsychotic treatment. The differential diagnosis and diagnostic evaluation of patients presenting with schizophrenia-like symptoms is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6962.html" rel="external">
          "Schizophrenia in adults: Clinical features, assessment, and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H412052916">
         <span class="h3">
          Co-occurring conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Co-occurring mental disorders, substance use disorders, and medical conditions contribute to the illness burden of patients with schizophrenia; if untreated, these conditions can impede effective treatment of schizophrenia. Medical and psychiatric evaluations should include assessment for co-occurring conditions, followed by treatment.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mental disorders – The identification and management of mental disorders most commonly co-occurring with schizophrenia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15259.html" rel="external">
          "Anxiety in schizophrenia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14791.html" rel="external">
          "Depression in schizophrenia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14629.html" rel="external">
          "Management of obsessive-compulsive disorder in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Substance use disorders – The identification and management of substance use disorders co-occurring with schizophrenia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7798.html" rel="external">
          "Co-occurring schizophrenia and substance use disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medical conditions – A patient with nonresponsive schizophrenia should receive a history and physical exam for factors contributing to their clinical status. As one prominent example, obesity is common in chronically ill patients with schizophrenia. Such patients should be evaluated for sleep apnea and, if present, receive treatment. (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H412052957">
         <span class="h3">
          Antipsychotic drug side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Side effects, such as akathisia, parkinsonism (including akinesia), sedation, and insomnia, need to be assessed and treated, as they can mimic ongoing agitation or negative symptoms, and can lead to functional disability as well as possibly a greater tendency for ongoing psychopathology and relapse. In such cases, a dose reduction may result in improvement. (See
         <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">
          "Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Side effect management'
         </a>
         .)
        </p>
        <p>
         Since efficacy can be affected by other prescribed medications or over the counter agents, a thorough evaluation of potential drug-drug interactions should also be performed [
         <a href="#rid14">
          14
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          Carbamazepine
         </a>
         reduces the levels of all antipsychotics that are metabolized by the liver with the exceptions of:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Amisulpride, which is excreted renally
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10174" href="/z/d/drug information/10174.html" rel="external">
          Paliperidone
         </a>
         , which does not undergo first pass metabolism
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Levels of
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         and
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         can be reduced in patients who start smoking, which stimulates the cytochrome P450 1A2 enzyme that is involved in the antipsychotics’ metabolism.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Levels of
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , which are metabolized by the cytochrome P450 2D6 enzyme, can be elevated by co-treatment with
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         and
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         that are metabolized by the same enzyme system.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H412053528">
         <span class="h3">
          Medication nonadherence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonadherence to antipsychotic drugs is often overlooked by patients and clinicians, yet it is a common reason for pseudoresistance. As an example, a 2018 study found that 35 percent of individuals provisionally diagnosed with treatment-resistant schizophrenia had a subtherapeutic antipsychotic plasma level [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Nonadherence should be considered a potential reason for nonresponse until proven otherwise. Options for evaluating the role of nonadherence include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normalize nonadherence as a common consequence of having to take drugs daily and ask the patient about missed or lower-than-prescribed doses in a nonjudgmental way.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arrange for supervised medication intake, which may be easier to observe if the antipsychotic is given as an orally dissolving or liquid formulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Check a blood level of the antipsychotic drug. An absent level or a low level despite relatively high doses indicate nonadherence (or unusual metabolism).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Provide the patient with at trial of a long-acting injectable (LAI) antipsychotic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         LAI antipsychotics should not be reserved only for established nonadherence but should be used in most patients with schizophrenia needing antipsychotic medication. Epidemiologic studies suggest that LAI antipsychotics have 20 to 30 percent greater efficacy for reducing hospitalization and mortality compared with their daily oral counterparts, most likely because of assured adherence [
         <a href="#rid16">
          16-18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15250.html" rel="external">
          "Schizophrenia in adults: Pharmacotherapy with long-acting injectable antipsychotic medication"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Technology-assisted strategies may have a role in facilitating treatment adherence with antipsychotic drugs if acceptable to the patient in shared decision-making.
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          Aripiprazole
         </a>
         was approved by the Food and Drug Administration of the United States as the first “digital medicine” [
         <a href="#rid19">
          19
         </a>
         ]. This drug contains a biodegradable chip that signals to a torso-worn patch when it has been swallowed, and patients can decide whether to share this information with the clinician and others [
         <a href="#rid20">
          20
         </a>
         ]. Additionally, some online platforms and applications remind patients to take their prescribed drugs [
         <a href="#rid21">
          21
         </a>
         ]. The use of such technologies to improve treatment adherence is only emerging; clinical trials are needed to determine whether they improve adherence and clinical outcomes [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3727929881">
         <span class="h2">
          Adequacy of antipsychotic trials
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to designating a schizophrenia patient as treatment resistant, prior antipsychotic trials should be evaluated for their adequacy. Was it continued for at least six weeks at the maximally tolerated dose within the medication’s recommended range? (See
         <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">
          "Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Treatment-resistant schizophrenia'
         </a>
         .)
        </p>
        <p>
         Additional strategies for optimizing antipsychotic pharmacotherapy for schizophrenia  (
         <a class="graphic graphic_table graphicRef60624" href="/z/d/graphic/60624.html" rel="external">
          table 1
         </a>
         ) include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antipsychotic dose escalation above recommended dose
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Switching to a different non-clozapine antipsychotic
        </p>
        <p>
        </p>
        <p>
         Clinical trials of these strategies have failed to find consistent, convincing evidence of efficacy. Most of the trials have been limited by small sample sizes, and inconsistent or absent criteria for prior antipsychotic treatment or degree of response. The role of medication adherence was rarely formally assessed. Most trials were of short duration, leaving the long-term maintenance effect of the strategies unclear.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antipsychotic dose escalation – An antipsychotic trial should be conducted at the highest tolerated dose within the maximum recommended dose range prior to concluding that the clinical response to the medication was inadequate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Dose escalation beyond recommended maximum antipsychotic doses have not been supported by clinical trials:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 2015 meta-analysis of five randomized clinical trials compared dose escalation beyond recommended ranges versus treatment continuation with doses in the recommended range in a pooled total of 348 patients with schizophrenia. No differences were observed in Positive and Negative Syndrome Scale (PANSS)/Brief Psychiatric Rating Scale score change between groups [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 2018 Cochrane review of 10 randomized controlled trials with 675 schizophrenia patients did not find a clear differences between dose increase and dose maintenance in the rate of clinically relevant responses (risk ratio = 1.09, 95% CI 0.86-1.40), PANSS total score change (standardized mean difference = -1.44, 95% CI -6.85 to 3.97), or study discontinuation due to adverse effects (risk ratio = 1.63, 95% CI 0.52-5.07) [
         <a href="#rid24">
          24
         </a>
         ]. We do not generally recommend dose increases of antipsychotics above doses recommended by the manufacturer [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Switching antipsychotics – There is little empirical support for the efficacy of switching from one non-clozapine antipsychotic to another after an inadequate clinical response to an antipsychotic trial.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A retrospective data analysis of 244 patients with first-episode schizophrenia found that only 16.6 percent of individuals who changed antipsychotics after failing to respond to the first drug responded to the switch [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Comparing approaches – A randomized clinical trial comparing dose escalation versus switching antipsychotics in patients with schizophrenia after an antipsychotic trial resulting in nonresponse did not find a difference between groups [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H257568719">
         <span class="h2">
          Adequacy of nonpharmacologic treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The patient’s nonpharmacologic treatment should be evaluated and optimized prior to diagnosing treatment resistance.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Triggers and stressors
         </strong>
         – Triggers for worsening symptoms of schizophrenia, as well as stressors and factors interfering with effective treatment, need to be identified and addressed as much as possible. In this context, the strengths of the individual and the potential impact of the support system need to be evaluated and utilized to help overcome treatment refractoriness to the extent possible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychosocial interventions
         </strong>
         – Although psychosocial interventions given alone are not sufficiently effective in schizophrenia, providing them as an adjunct to antipsychotic medication has been found to improve patient outcomes. Cognitive-behavioral therapy (CBT) directly focuses on symptom control; the other interventions can reduce symptoms indirectly in treatment-resistant patients by reducing patient or family stress, improving adherence, or providing outreach that helps patients remain in the community; skills training can improve functioning. Patients with treatment-resistant schizophrenia and the following indications should be provided a trial of the associated intervention:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cognitive-behavioral therapy
         </strong>
         – In patients who experience persistent delusions or hallucinations despite adequate trials of antipsychotic medication [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15774.html" rel="external">
          "Schizophrenia in adults: Psychosocial management", section on 'Cognitive-behavioral therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Multiple meta-analyses of clinical trials of adjunctive CBT for patients with schizophrenia found mixed evidence of efficacy in patients with an incomplete response to antipsychotics. In our clinical experience, despite the mixed findings, CBT can be helpful and lacks side effects. CBT should be provided for individuals with treatment-resistant schizophrenia when available.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A 2018 meta-analysis of 60 randomized clinical trials with 5992 patients with schizophrenia found no convincing evidence for the superiority of CBT versus usual care for relapse, mental state, quality of life, social function, or satisfaction with care [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A 2015 meta-analysis of 35 randomized trials with 2312 patients with schizophrenia found no benefits of CBT for negative symptoms compared with control conditions [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A 2014 meta-analysis of 34 clinical trials of CBT for psychosis with 4791 patients with schizophrenia found small effect sizes favoring CBT over control for the reduction of overall symptoms (Hedges’ g = -0.33, 95% CI -0.47 to -0.19) [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Family psychoeducational interventions
         </strong>
         – In patients who have had a recent psychotic relapse and have significant ongoing contact with family members [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15774.html" rel="external">
          "Schizophrenia in adults: Psychosocial management", section on 'Family-based Interventions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Social skills training
         </strong>
         – In patients who have deficits in skills needed for everyday activities [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15774.html" rel="external">
          "Schizophrenia in adults: Psychosocial management", section on 'Social skills training'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Assertive community treatment –
         </strong>
         In patients with a recent history of repeated hospitalization or homelessness [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/105343.html" rel="external">
          "Assertive community treatment for patients with severe mental illness"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Crisis intervention –
         </strong>
         In patients with an acute psychosocial stressor who are in emotional crisis, leading to symptom exacerbation [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3014558684">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the patient’s clinical response remains inadequate despite addressing these factors, and Treatment Response and Resistance in Psychosis Working Group criteria are met, treatment-resistant schizophrenia should be diagnosed. (See
         <a class="local">
          'Definition'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1258093965">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of patients with treatment-resistant schizophrenia includes the determination of
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         eligibility, treatment with clozapine (preferably) or an alternative, and for patients who continue to respond inadequately, trials of other interventions with lesser evidence supporting efficacy.
        </p>
        <p class="headingAnchor" id="H17442645">
         <span class="h2">
          Clozapine
         </span>
        </p>
        <p class="headingAnchor" id="H2368248323">
         <span class="h3">
          Eligibility
         </span>
         <span class="headingEndMark">
          —
         </span>
         To be eligible for a
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         trial, a patient with treatment-resistant schizophrenia (see
         <a class="local">
          'Definition'
         </a>
         above) should additionally meet the following criteria:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absolute neutrophil count ≥1500 cells/microliter
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Determination by the physician as well as the patient and family if possible that the benefits of
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         outweighing the risks
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ability to adhere to treatment monitoring
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient/family agreement
        </p>
        <p>
        </p>
        <p>
         Guidelines for prescribing
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/14772.html" rel="external">
          "Schizophrenia in adults: Guidelines for prescribing clozapine"
         </a>
         .)
        </p>
        <p>
         Although some have advocated reducing the number of antipsychotic trials required by the Treatment Response and Resistance in Psychosis (TRRIP) Working Group definition from two to one before
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         is used [
         <a href="#rid35">
          35,36
         </a>
         ], we believe this recommendation is premature given the limitations of the supporting data and the risks of agranulocytosis and other serious side effects with clozapine [
         <a href="#rid37">
          37
         </a>
         ]. Studies suggest some advantages to using clozapine in individuals with only a partial response to non-clozapine antipsychotics (as opposed to the “less than minimal response” recommended by the TRRIP criteria) [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H85760356">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Randomized trials have shown that
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         has greater efficacy compared with other antipsychotics in treating patients with schizophrenia who have responded poorly to prior antipsychotic trials. These findings have been summarized in head-to-head and network meta-analyses [
         <a href="#rid8">
          8,12,13
         </a>
         ], as well as in comparative effectiveness studies [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         A meta-analysis comparing the efficacy of
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         with first or second generation antipsychotics in 25 trials including 2364 patients found that patients treated with clozapine experienced greater clinical improvement in total symptoms (standard mean difference [SMD] = -0.29, 95% CI -0.49 to -0.09) [
         <a href="#rid8">
          8
         </a>
         ]. When only long-term trials were included in the analysis, greater improvement was seen (SMD = -0.39, 95% CI -0.61 to -0.17). This clinical advantage was observed in long-term studies for positive symptoms (SMD = -0.27, 95% CI -0.47 to -0.08) and negative symptoms (SMD = -0.25, 95% CI -0.40 to -0.10).
        </p>
        <p>
         As an example, a randomized trial compared treatment with
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         (up to 900 mg daily) with
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         (up to 1800 mg daily) in 268 patients with schizophrenia who had failed to respond to at least three different first-generation antipsychotics [
         <a href="#rid11">
          11
         </a>
         ]. After a six-week treatment period, a greater proportion of clozapine-treated patients experienced a clinically significant response compared with patients in the chlorpromazine-treated group (30 versus 4 percent). A clinically significant response was defined a priori based on scores from the Brief Psychiatric Rating Scale and the Clinical Global Impressions scale.
        </p>
        <p>
         A 2016 network meta-analysis comparing
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         with first- or second-generation antipsychotics in 40 randomized trials with 5172 patients with treatment-resistant schizophrenia found mixed results [
         <a href="#rid12">
          12
         </a>
         ]. Methodologic issues in the included trials, for example, the potential exclusion of the most severely treatment-resistant patients, and use of relatively low clozapine doses in some trials, preclude drawing firm conclusions from the study [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         Analysis of prospectively collected data from a national cohort of individuals diagnosed with schizophrenia in Sweden demonstrated consistently greater effectiveness of
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         compared with oral
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , the most frequently prescribed drug. Patients receiving clozapine had a lower risk of hospitalization compared with patients prescribed olanzapine (hazard ratio = 0.58, 95% CI 0.53-0.63) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H967157">
         <span class="h3">
          Administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Guidelines for prescribing
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         , including medical contraindications, pharmacology, dosing, monitoring, and adverse effects are described separately. (See
         <a class="medical medical_review" href="/z/d/html/14772.html" rel="external">
          "Schizophrenia in adults: Guidelines for prescribing clozapine"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H257568422">
         <span class="h3">
          Discontinuation
         </span>
         <span class="headingEndMark">
          —
         </span>
         If tolerated and without adverse consequences, a
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         trial should be given for at least 24 weeks in patients with treatment-resistant schizophrenia, as studies have found clinical improvement can continue for this duration [
         <a href="#rid8">
          8,41
         </a>
         ]. Additionally, adequate clozapine exposure should be measured by therapeutic drug monitoring confirming that plasma levels are above 350 ng/dl. (See
         <a class="medical medical_review" href="/z/d/html/14772.html" rel="external">
          "Schizophrenia in adults: Guidelines for prescribing clozapine"
         </a>
         .)
        </p>
        <p>
         Just as shared decision-making should if possible precede the start of
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         , the decision to discontinue clozapine due to lack of efficacy should be discussed with the patient and family. Some of clozapine’s benefits involve patient satisfaction, increased well-being, and functionality that are not always as obvious to clinicians as they might be to patients and family members. The benefits of clozapine should be sufficiently clear to justify continuation of the drug but should not be limited to symptoms of psychosis.
        </p>
        <p class="headingAnchor" id="H1536388995">
         <span class="h2">
          Alternatives for patients ineligible for or refusing clozapine
         </span>
         <span class="headingEndMark">
          —
         </span>
         A significant proportion of patients with treatment-resistant schizophrenia have contraindications to
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         or refuse the medication. Because the evidence of efficacy of alternative treatments is limited, we suggest that, prior to their use, patients are carefully reviewed to ensure that:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient meets TRRIP criteria for treatment-resistant schizophrenia. (See
         <a class="local">
          'Definition'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The adequacy of the patient’s prior antipsychotic trials has been evaluated and, if inadequate, that optimized antipsychotic treatment was insufficiently effective. (See
         <a class="local">
          'Adequacy of antipsychotic trials'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The treatment team, patient, and family have determined that
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         is not a viable treatment.
        </p>
        <p>
        </p>
        <p>
         Several alternatives to
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         have been tested in randomized clinical trials of patients with treatment-resistant schizophrenia, but most of the findings are mixed and are from trials with methodologic limitations. Nonetheless, these treatments are used by patients who have responded inadequately to prior treatments and have a clinical status and health-related quality of life that is sufficiently poor that the patient, family, and treatment team have decided that the treatments are justified despite the very limited evidence of efficacy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electroconvulsive therapy (ECT)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          Lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Repetitive transcranial magnetic stimulation (rTMS)
        </p>
        <p>
        </p>
        <p>
         For patients with treatment-resistant schizophrenia for whom
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         is not an option, we suggest antipsychotic augmentation of antipsychotic treatment with ECT rather than medication or rTMS (see
         <a class="local">
          'Electroconvulsive therapy'
         </a>
         below). This recommendation is based on the indirect though robust evidence of efficacy for ECT augmenting clozapine in treatment-resistant schizophrenia (see
         <a class="local">
          'Treatment of clozapine-resistant schizophrenia'
         </a>
         below) rather than on the sparse data comparing it with antipsychotic monotherapy. (See
         <a class="local">
          'Electroconvulsive therapy'
         </a>
         below.)
        </p>
        <p>
         For patients who do not respond to an eight-week trial of ECT augmentation (delivered two to three times per week), we suggest treatment with
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         (also an eight-week trial that if unsuccessful should be followed by trials of
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         and
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         ), followed by a trial of rTMS. This ordering is based on the consistency of the evidence supporting each intervention. This “hierarchy” of recommendations is based on indirect evidence, as there are no data comparing these treatments head-to-head. (See
         <a class="local">
          'Electroconvulsive therapy'
         </a>
         below and
         <a class="local">
          'Medication strategies'
         </a>
         below and
         <a class="local">
          'Repetitive transcranial magnetic stimulation (rTMS)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3859220059">
         <span class="h3">
          Electroconvulsive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A 2016 meta-analysis of 11 randomized clinical trials with 818 participants with schizophrenia trials compared ECT augmenting a non-clozapine antipsychotic with a non-clozapine antipsychotic alone [
         <a href="#rid42">
          42
         </a>
         ]. ECT was superior to control for total symptom improvement (SMD = -0.67, 95% CI -0.95 to -0.39), and study defined response (risk ratio = 1.48, 95% CI 1.24-1.77), with a number needed to treat (NNT) between four and nine [
         <a href="#rid42">
          42
         </a>
         ]. The most frequent side effects of ECT were headache, with a number needed to harm (NNH) of six, and memory impairment, with an NNH of three.
        </p>
        <p>
         Other trials have tested ECT augmentation of antipsychotic drugs in antipsychotic-resistant patients without regard to whether the patient was receiving
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         or another antipsychotic drug. A meta-analysis of 18 randomized clinical trials (17 conducted in China) with 1394 schizophrenia patients for whom clozapine resistance had not been systematically confirmed found that ECT augmentation of antipsychotic treatment was superior to antipsychotic medication treatment alone on several outcomes including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endpoint assessment (67.7 versus 41.4 percent, risk ratio = 1.66, 95% CI 1.38-1.99; NNT = 4)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Study-defined response at post-ECT assessment (53.6 versus 25.4 percent, risk ratio = 1.94, 95% CI 1.59-2.36; number needed to treat [NNT] = 3)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Remission at post-ECT assessment (13.3 versus 3.7 percent, risk ratio = 3.28, 95% CI 1.80-5.99; NNT = 13)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endpoint assessment (23.6 versus 13.3 percent, risk ratio = 1.80, 95% CI 1.39-2.35; NNT = 14) [
         <a href="#rid43">
          43
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Patient-reported memory impairment (24.2 versus 0 percent; NNH = 4) and headache (14.5 versus 1.6 percent; NNH = 8) occurred more frequently with patients receiving adjunctive ECT.
        </p>
        <p class="headingAnchor" id="H365620771">
         <span class="h3">
          Medication strategies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Augmentation of a non-clozapine antipsychotic with other medications has not shown convincing evidence of efficacy in clinical trials. A meta-analysis of 381 randomized clinical trials published in 2017 identified 42 antipsychotic augmentation strategies that were initially found to be superior to placebo: for total psychopathology (14), for positive symptoms (6) and for negative symptoms (4), with effect sizes that ranged from small (0.2) to large (0.8 to 1.3) [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         Despite statistically significant results for some outcomes, the findings and methodologic limitations of these trials leads us to conclude that none of the 42 augmentation strategies are supported by sufficient evidence of efficacy from meta-analysis to recommend its use. Limitations included small samples, lack of replication in a large single trial, absence of testing in samples of patients with well-defined treatment-resistant schizophrenia, heterogeneity of results, and publication bias. An inverse relationship was found between the quality of the meta-analyzed clinical trials and the effect size of any advantage [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         Medications with the best balance between effect size versus the risk of bias were:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          Lamotrigine
         </a>
         (typical dose: 100 to 200 mg/day) – Three randomized trials found adjunctive lamotrigine to be superior to placebo in reducing symptoms of antipsychotic-treated schizophrenia (standard mean difference= -0.73 95% CI -1.26 to -0.20).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          Minocycline
         </a>
         (typical dose 100 to 200 mg/day) – A meta-analysis of eight randomized trials compared adjunctive minocycline with placebo in 581 patients with antipsychotic-treated schizophrenia [
         <a href="#rid45">
          45
         </a>
         ]. Patients treated with minocycline experienced reduced symptoms compared with placebo (SMD = -0.59 95% CI -0.15 to 0.03).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          Topiramate
         </a>
         (typical dose 100 to 400 mg/day) – A meta-analysis of 13 randomized trials with 651 antipsychotic treated patients with schizophrenia compared topiramate augmentation with placebo augmentation or antipsychotic monotherapy. Topiramate outperformed the comparator on reduction in symptoms (SMD = -0.58, 95% CI -0.82 to -0.35).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H754479497">
         <span class="h3">
          Repetitive transcranial magnetic stimulation (rTMS)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mixed results have been found in short-term clinical trials of rTMS in schizophrenia; there is an absence of long-term evidence.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2018 meta-analysis of 22 randomized clinical randomized trials with 827 schizophrenia patients found rTMS applied to the frontal cortex reduced negative symptoms in patients with schizophrenia already being treated with antipsychotic drugs compared with antipsychotic treatment alone with an effect size = 0.64 (95% CI 0.32-0.96) [
         <a href="#rid46">
          46
         </a>
         ]. Trials including younger patients found larger effect sizes compared with trials including older patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2015 Cochrane systematic review and meta-analysis found no difference in overall symptoms comparing temporoparietal rTMS plus standard treatment with standard treatment alone [
         <a href="#rid47">
          47
         </a>
         ]. More recently, a clinical trial found no difference in auditory hallucinations when temporoparietal rTMS was compared with placebo treatment in individuals with antipsychotic-resistant hallucinations [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An updated meta-analysis investigated the effect of transcranial direct current stimulation (tDCS), a neuromodulatory intervention that uses direct current, and of rTMS, as adjunctive treatments in schizophrenia [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In seven randomized clinical trials in 105 patients with schizophrenia, compared with sham, tDCS reduced negative symptoms (Hedge's g = -0.63), with a nonsignificant trend toward reducing positive and overall symptoms. Efficacy for positive but not negative symptoms was linearly associated with cumulative tDCS stimulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In 30 randomized trials of rTMS in 768 patients with schizophrenia, compared with sham, rTMS reduced hallucinations (Hedge’s g = -0.51) and negative symptoms (Hedge’s g = -0.49) but was associated with a modest nonsignificant trend toward worsening of some positive symptoms (Hedge’s g = 0.28).
        </p>
        <p>
        </p>
        <p>
         Side effects of rTMS include pain at the site of stimulation, muscle twitching during treatment sessions, posttreatment headache and toothache, and, rarely, seizures. Patients with a seizure disorder should not receive rTMS.
        </p>
        <p class="headingAnchor" id="H3803095663">
         <span class="h2">
          Treatment of clozapine-resistant schizophrenia
         </span>
         <span class="headingEndMark">
          —
         </span>
         We define
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         resistance as the failure to show adequate improvement after a 24-week trial of clozapine [
         <a href="#rid8">
          8,41
         </a>
         ]. Between 50 and 60 percent of patients with treatment-resistant schizophrenia fail to meet response criteria to clozapine after such a trial [
         <a href="#rid13">
          13,41
         </a>
         ]. These patients are often referred to as “ultra-treatment,” but the term “clozapine-resistant” is preferred to avoid confusion with patients who respond to ECT augmentation of clozapine, or with ECT-resistant patients.
        </p>
        <p>
         For clozapine-resistant patients with schizophrenia, we favor ECT augmentation of
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         rather than medication augmentation [
         <a href="#rid44">
          44,50
         </a>
         ]. Clinical trials of the medications below have very limited evidence of efficacy and multiple methodologic limitations, and therefore should be used only if ECT augmentation is not viable.
        </p>
        <p class="headingAnchor" id="H215714725">
         <span class="h3">
          Augmentation with electroconvulsive therapy (ECT)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Only one trial has tested ECT augmentation of
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         in schizophrenia patients with confirmed clozapine resistance, finding ECT augmentation to reduce schizophrenia symptoms compared with continuing clozapine treatment alone [
         <a href="#rid51">
          51
         </a>
         ]. The single-blind, eight-week trial randomly assigned 39 patients with clozapine-resistant schizophrenia to continue clozapine or to receive bilateral ECT (two to three sessions/week) along with continuing clozapine. Patients treated with ECT and clozapine were more likely to meet criteria for clinical response (≥40 percent reduction in psychosis) compared with patients receiving clozapine alone (50 versus 0 percent). The control group demonstrated a similar response to ECT upon crossing over to receive ECT after the randomized phase was completed. Two patients required the postponement of an ECT session because of mild confusion.
        </p>
        <p class="headingAnchor" id="H1476489726">
         <span class="h3">
          Augmentation with medication
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Non-clozapine antipsychotic
         </strong>
         – The addition of a non-clozapine antipsychotic to
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         for individuals with residual symptoms despite clozapine treatment is controversial. A meta-analysis of two randomized trials with a total of 626 patients found a benefit to clozapine augmentation with a first-generation antipsychotic (SMD = -0.52, 95% CI -0.90 to -0.14), and a second-generation antipsychotic (SMD = -0.52, 95% CI -0.93 to -0.11) compared with clozapine monotherapy, although these differences were not significant when only high quality studies were analyzed [
         <a href="#rid52">
          52
         </a>
         ]. Also, in an overview of meta-analyses of combination treatments, none of the meta-analyses of pharmacologic augmentation of clozapine yielded superior results to control [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Augmentation with
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         has been studied more extensively than other antipsychotics because of the unique pharmacodynamic characteristics of the second-generation antipsychotics. Analysis of data from a national registry of health care data in Finland found that individuals who were treated with
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         (the most efficacious monotherapy in the study) were 14 percent less likely to be hospitalized for psychosis during periods when they were also prescribed aripiprazole (hazard ratio = 0.86; 95% CI 0.79-0.94) [
         <a href="#rid53">
          53
         </a>
         ]. The effect of the combination was more pronounced in first-episode patients (hazard ratio = 0.78; 95% CI 0.63-0.96).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other medications
         </strong>
         – The combination of other drugs with
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         has been consistently ineffective in meta-analyses of randomized clinical trials, and for this reason their use is generally not recommended [
         <a href="#rid44">
          44
         </a>
         ]. Weak evidence provides some support for augmentation with first- or second-generation antipsychotics, and certain antidepressants (
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         ) for persistent negative symptoms. Still weaker evidence supports clozapine augmentation with mood-stabilizers, anticonvulsants, pro-glutamatergic agents [
         <a href="#rid54">
          54
         </a>
         ], rTMS, or tDCS [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H278450466">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117525.html" rel="external">
          "Society guideline links: Psychotic disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1754474114">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         While most patients show significant improvement in psychotic symptoms in response to antipsychotic drugs, a substantial proportion experience residual treatment-resistant symptoms. (See
         <a class="local">
          'Prevalence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To facilitate greater accuracy and reliability in the diagnosis of treatment-resistant schizophrenia, we favor the use of the minimal consensus-based criteria developed the Treatment Response and Resistance in Psychosis (TRRIP) Working Group (see
         <a class="local">
          'Definition'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Symptom severity – At least moderate symptom severity (&gt;3 in psychotic symptom items) as rated using a standardized scale (eg, Positive and Negative Syndrome Scale or Brief Psychiatric Rating Scale).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Functional impairment – At least moderate impairment measured using a validated scale (eg, Social and Occupational Functioning Assessment Scale).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prior treatment – At least two trials of ≥6 weeks at a therapeutic dose (equivalent to ≥600 mg
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         ) with adherence ≥80 percent of prescribed doses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Optimal TRRIP criteria further call for one of the two antipsychotic trials to be for a long-acting injectable antipsychotic (see
         <a class="medical medical_review" href="/z/d/html/15250.html" rel="external">
          "Schizophrenia in adults: Pharmacotherapy with long-acting injectable antipsychotic medication"
         </a>
         ) and for antipsychotic adherence to be established longitudinally with ≥2 plasma levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior to making a diagnosis of treatment-resistant schizophrenia, the clinician should rule out or address causes of pseudoresistance, including (see
         <a class="local">
          'Assess for pseudoresistance'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Misdiagnosis of primary disorder
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Co-occurring mental or substance-use disorders, or medical conditions
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antipsychotic drug side effects
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Medication nonadherence
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Drug-drug interactions
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient’s antipsychotic drug treatment  (
         <a class="graphic graphic_table graphicRef60624" href="/z/d/graphic/60624.html" rel="external">
          table 1
         </a>
         ) and nonpharmacologic treatment should be evaluated and optimized (see
         <a class="local">
          'Adequacy of nonpharmacologic treatment'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with treatment-resistant schizophrenia as defined by the TRRIP criteria who meet the
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         eligibility criteria below, we recommend first-line treatment with clozapine rather than other medications (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). (See
         <a class="local">
          'Clozapine'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14772.html" rel="external">
          "Schizophrenia in adults: Guidelines for prescribing clozapine"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Absolute neutrophil count ≥1500 cells/microliter
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Determination by physician as well as the patient and family if possible that the benefits of
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         outweigh the risks
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ability to adhere to treatment monitoring
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with treatment-resistant schizophrenia who are not eligible for (or refuse)
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         , we favor augmentation of a non-clozapine antipsychotic with electroconvulsive therapy (ECT) rather than medication or repetitive transcranial magnetic stimulation. If ECT is not effective, we would treat with
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         .
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          Minocycline
         </a>
         or
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         are reasonable alternatives. (See
         <a class="local">
          'Alternatives for patients ineligible for or refusing clozapine'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For clozapine-resistant patients with schizophrenia, we favor ECT augmentation of
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         rather than medication; however, no approach has shown convincing evidence of efficacy. (See
         <a class="local">
          'Treatment of clozapine-resistant schizophrenia'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Correll CU, Kishimoto T, Nielsen J, Kane JM. Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther 2011; 33:B16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howes OD, McCutcheon R, Agid O, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry 2017; 174:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leucht S, Leucht C, Huhn M, et al. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. Am J Psychiatry 2017; 174:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agid O, Arenovich T, Sajeev G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 2011; 72:1439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Hert M, van Winkel R, Wampers M, et al. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res 2007; 92:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demjaha A, Lappin JM, Stahl D, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med 2017; 47:1981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lally J, Ajnakina O, Di Forti M, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med 2016; 46:3231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016; 209:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thien K, O'Donoghue B. Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: A literature review. Early Interv Psychiatry 2019; 13:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olfson M, Gerhard T, Crystal S, Stroup TS. Clozapine for Schizophrenia: State Variation in Evidence-Based Practice. Psychiatr Serv 2016; 67:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samara MT, Dold M, Gianatsi M, et al. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. JAMA Psychiatry 2016; 73:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siskind D, Siskind V, Kisely S. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. Can J Psychiatry 2017; 62:772.
          </a>
         </li>
         <li class="breakAll">
          Flockhart D. Drug Interactions: Cytochrome P450 Drug Interaction Table. 2007. http://medicine.iupui.edu/clinpharm/ddis/table.aspx (Accessed on August 15, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCutcheon R, Beck K, D'Ambrosio E, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand 2018; 137:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lähteenvuo M, Tanskanen A, Taipale H, et al. Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder. JAMA Psychiatry 2018; 75:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res 2018; 197:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taipale H, Mehtälä J, Tanskanen A, Tiihonen J. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up. Schizophr Bull 2018; 44:1381.
          </a>
         </li>
         <li class="breakAll">
          https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm584933.htm (Accessed on April 25, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Profit D, Rohatagi S, Zhao C, et al. Developing a Digital Medicine System in Psychiatry: Ingestion Detection Rate and Latency Period. J Clin Psychiatry 2016; 77:e1095.
          </a>
         </li>
         <li class="breakAll">
          https://mindtools.io/.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deegan PE, Drake RE. Shared decision making and medication management in the recovery process. Psychiatr Serv 2006; 57:1636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dold M, Fugger G, Aigner M, et al. Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Res 2015; 166:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samara MT, Klupp E, Helfer B, et al. Increasing antipsychotic dose for non response in schizophrenia. Cochrane Database Syst Rev 2018; 5:CD011883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012; 13:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samara MT, Klupp E, Helfer B, et al. Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. Cochrane Database Syst Rev 2018; 5:CD011884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 2008; 34:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones C, Hacker D, Xia J, et al. Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia. Cochrane Database Syst Rev 2018; 12:CD007964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velthorst E, Koeter M, van der Gaag M, et al. Adapted cognitive-behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression. Psychol Med 2015; 45:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauhar S, McKenna PJ, Radua J, et al. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry 2014; 204:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev 2010; :CD000088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurtz MM, Mueser KT. A meta-analysis of controlled research on social skills training for schizophrenia. J Consult Clin Psychol 2008; 76:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coldwell CM, Bender WS. The effectiveness of assertive community treatment for homeless populations with severe mental illness: a meta-analysis. Am J Psychiatry 2007; 164:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joy CB, Adams CE, Rice K. Crisis intervention for people with severe mental illnesses. Cochrane Database Syst Rev 2006; :CD001087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahn RS, Winter van Rossum I, Leucht S, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry 2018; 5:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okhuijsen-Pfeifer C, Huijsman EAH, Hasan A, et al. Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis. Acta Psychiatr Scand 2018; 138:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Homan P, Kane JM. Clozapine as an early-stage treatment. Acta Psychiatr Scand 2018; 138:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schooler NR, Marder SR, Chengappa KN, et al. Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. J Clin Psychiatry 2016; 77:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia. JAMA Psychiatry 2017; 74:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kane JM, Correll CU. The Role of Clozapine in Treatment-Resistant Schizophrenia. JAMA Psychiatry 2016; 73:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151:1744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng W, Cao XL, Ungvari GS, et al. Electroconvulsive Therapy Added to Non-Clozapine Antipsychotic Medication for Treatment Resistant Schizophrenia: Meta-Analysis of Randomized Controlled Trials. PLoS One 2016; 11:e0156510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang W, Pu C, Jiang J, et al. Efficacy and safety of treating patients with refractory schizophrenia with antipsychotic medication and adjunctive electroconvulsive therapy: a systematic review and meta-analysis. Shanghai Arch Psychiatry 2015; 27:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correll CU, Rubio JM, Inczedy-Farkas G, et al. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. JAMA Psychiatry 2017; 74:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiang YQ, Zheng W, Wang SB, et al. Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol 2017; 27:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aleman A, Enriquez-Geppert S, Knegtering H, Dlabac-de Lange JJ. Moderate effects of noninvasive brain stimulation of the frontal cortex for improving negative symptoms in schizophrenia: Meta-analysis of controlled trials. Neurosci Biobehav Rev 2018; 89:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dougall N, Maayan N, Soares-Weiser K, et al. Transcranial magnetic stimulation (TMS) for schizophrenia. Cochrane Database Syst Rev 2015; :CD006081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koops S, van Dellen E, Schutte MJ, et al. Theta Burst Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations: Negative Findings From a Double-Blind-Randomized Trial. Schizophr Bull 2016; 42:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy NI, Lee WH, Frangou S. Efficacy of non-invasive brain stimulation on the symptom dimensions of schizophrenia: A meta-analysis of randomized controlled trials. Eur Psychiatry 2018; 49:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner E, Löhrs L, Siskind D, et al. Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance. J Psychopharmacol 2019; 33:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petrides G, Malur C, Braga RJ, et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry 2015; 172:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galling B, Roldán A, Hagi K, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 2017; 16:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiihonen J, Taipale H, Mehtälä J, et al. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA Psychiatry 2019; 76:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis D. A possible role for sarcosine in the management of schizophrenia. Br J Psychiatry 2019; 215:697.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14808 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22177377" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Quantifying clinical relevance in the treatment of schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27919182" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28541090" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21457676" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17336500" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Remission criteria for schizophrenia: evaluation in a large naturalistic cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28395674" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27605254" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27388573" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29984888" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: A literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26522679" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clozapine for Schizophrenia: State Variation in Evidence-Based Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3046553" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26842482" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28655284" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28655284" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29072776" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29490359" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29274734" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29272458" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29272458" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27379966" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Developing a Digital Medicine System in Psychiatry: Ingestion Detection Rate and Latency Period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27379966" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Developing a Digital Medicine System in Psychiatry: Ingestion Detection Rate and Latency Period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17085613" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Shared decision making and medication management in the recovery process.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26008883" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29750432" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Increasing antipsychotic dose for non response in schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22834451" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29749607" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17962231" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30572373" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24993642" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Adapted cognitive-behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24385461" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21154340" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Family intervention for schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18540742" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A meta-analysis of controlled research on social skills training for schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17329462" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The effectiveness of assertive community treatment for homeless populations with severe mental illness: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17054133" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Crisis intervention for people with severe mental illnesses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30115598" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30218445" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30240545" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Clozapine as an early-stage treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27035871" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28593216" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26841681" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The Role of Clozapine in Treatment-Resistant Schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7977880" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27285996" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Electroconvulsive Therapy Added to Non-Clozapine Antipsychotic Medication for Treatment Resistant Schizophrenia: Meta-Analysis of Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26549957" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Efficacy and safety of treating patients with refractory schizophrenia with antipsychotic medication and adjunctive electroconvulsive therapy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28514486" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27919523" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29471017" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Moderate effects of noninvasive brain stimulation of the frontal cortex for improving negative symptoms in schizophrenia: Meta-analysis of controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26289586" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Transcranial magnetic stimulation (TMS) for schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26221051" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Theta Burst Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations: Negative Findings From a Double-Blind-Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29413808" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Efficacy of non-invasive brain stimulation on the symptom dimensions of schizophrenia: A meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30696332" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25157964" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28127934" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30785608" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31685041" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A possible role for sarcosine in the management of schizophrenia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
